Drugs / PY314
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04691375 | Oct 2020 → Aug 2023 | colorectal cancer, lung adenocarcinoma, ovarian carcinoma, renal cell carcinoma +1 | Ikena Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PY314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04691375 ↗ |
| Action | Deplete | “PY314 is a humanized monoclonal antibody targeting TREM2 that depletes tumor-associated macrophages.” PMID 38372949 ↗ Feb 2024 |
| Modality | Monoclonal antibody | “PY314 is a humanized monoclonal antibody targeting TREM2 that depletes tumor-associated macrophages.” PMID 38372949 ↗ Feb 2024 |
| Target | TREM2 | “PY314 is a humanized monoclonal antibody targeting TREM2 that depletes tumor-associated macrophages.” PMID 38372949 ↗ Feb 2024 |